AbbVie Reaffirms 2026 Guidance After Closing $10.9 Billion Apogee Acquisition
AbbVie completed its acquisition of Apogee Therapeutics for $10.9 billion in cash, adding two late-stage immunology...
Moderna raises $2.6 billion in zero-coupon convertibles as revenue collapses, betting oncology turnaround
Moderna priced a $2.6 billion offering of convertible senior notes due 2032 on August 28, 2026,...
Caterpillar renews three-year credit facility with unchanged $4 billion commitment as borrowing costs shift to SOFR
Caterpillar Inc. has executed a fifth amendment to its revolving credit agreement, dated August 27, 2026,...
Boeing renews 364-day credit line as operating margin stays thin at 4.8%
Boeing has executed a new 364-day revolving credit agreement dated August 24, 2026, replacing its prior...
Walmart’s operating income surges 28.8% as tariff refunds and eCommerce gains offset pricing pressure
Walmart reported second-quarter revenue of $187.9 billion, up 5.9% from the prior year (5.1% in constant...
Honeywell elevates Building Automation chief to lead Process Technology as Ken West departs
Honeywell Technologies announced a leadership reshuffle on Aug. 19, 2026, promoting Billal Hammoud from President and...
Lowe’s cuts full-year profit guidance as DIY weakness persists despite Pro strength
Lowe's Companies narrowed its fiscal 2026 earnings outlook on Wednesday, reducing adjusted diluted EPS guidance to...
NVIDIA Secures 4.25 IT-GW Ohio Data Center Capacity and Invests $1.5B in SB Energy to Lock in AI Infrastructure
NVIDIA has committed $1.5 billion to SB Energy and secured exclusive rights to 4.25 IT-GW of...
Target secures five-year $5 billion revolver as operating margin pressures persist
Target Corporation has entered into a five-year revolving credit facility dated August 14, 2026, with Bank...
Tonix’s TONMYA sales nearly triple in Q2 as payer coverage reaches 43% of U.S. lives
Tonix Pharmaceuticals reported second-quarter 2026 net sales of approximately $11 million for TONMYA, its fibromyalgia treatment,...
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.